Adherence in Acute Coronary Syndrome

Published Online: Monday, March 25, 2013
Follow Pharmacy_Times:
In this video, from AJMCtv, Jeffrey Berger, MD, assistant professor at NYU Langone Medical Center, discusses how research can help increase adherence to therapies among acute coronary syndrome (ACS) patients.

Related Articles
The first FDA-approved “smart pill” documents medication adherence and physiologic response.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
A new study presented today at American Heart Association’s Scientific Sessions suggests clinicians may have more evidenced-based options when considering preventative therapy for high-risk acute coronary syndrome patients.
Adding another type of cholesterol-lowering drug to statin therapy can better prevent heart attacks and strokes in high-risk patients with acute coronary syndrome.
Latest Issues
$auto_registration$